Why cartilage loss causes pain that peaks at night

For many people with hip arthritis, the pattern follows a familiar arc: pain that felt manageable during a walk or a working day becomes far harder to ignore once they lie down. That reversal is not imagined, and it is not simply tiredness lowering the pain threshold.

Healthy articular cartilage at the femoral head and acetabulum acts as a pressure-distributing buffer, absorbing load and allowing smooth movement. When that cartilage thins or develops focal Grade III or IV defects — whether through degenerative wear, femoroacetabular impingement (FAI), or post-traumatic change — the underlying subchondral bone loses its protection. Bone-on-bone contact generates pain, and intra-articular pressure rises as the joint's mechanical environment deteriorates.

During the day, the compressive forces of walking concentrate pain on weight-bearing surfaces; briefly taking weight off the limb offers some relief. At night, that mechanism stops working. Resting position concentrates load on the posterior capsule and the posterior femoral head — precisely the surfaces most often affected by FAI-related chondral wear and diffuse cartilage thinning. Synovial inflammation does not switch off with the lights, and intra-articular pressure is not relieved by lying still.

The clinical significance of this nocturnal pattern is well recognised. Hip pain that disrupts sleep is considered a threshold indicator that conservative measures — rest, analgesia, physiotherapy — are no longer sufficient to manage the underlying joint environment, and that intra-articular intervention warrants assessment. It is a signal about the state of the joint, not a coincidence of timing.

What ChondroFiller is and how it works in the hip

ChondroFiller® (Meidrix Biomedicals) is a CE-marked Class III medical device — an acellular solution of murine-derived Type I collagen that, once injected, polymerises within minutes into a gel scaffold inside the joint. Unlike hyaluronic acid, which provides palliative lubrication without any regenerative action, ChondroFiller operates through two simultaneous mechanisms.

Mechanically, the gelled collagen forms a viscoelastic cushion across the worn articular surface, absorbing friction between the femoral head and acetabulum. Biologically, the scaffold acts as a chemotactic matrix: the patient's own progenitor cells migrate into it from the surrounding synovium and subchondral bone, then differentiate into chondrocytes at the defect site. This is acellular matrix-induced chondrogenesis — in plain terms, the scaffold creates the conditions for the body to carry out its own repair. The injection does not directly regrow cartilage; it provides the architecture within which the patient's cells can do so.

For nocturnal hip pain, that dual action is directly relevant to the subchondral-exposure mechanism outlined above. The compressive buffer restored between the femoral head and acetabulum addresses bone-on-bone contact that lying-down position cannot relieve. A rebuilt viscoelastic cushion reduces the intra-articular pressure changes that persist through the night regardless of posture — giving the mechanical rationale for ChondroFiller a specific logic in patients whose pain peaks precisely when rest should, but does not, offer relief.

How the ultrasound-guided hip injection works

Reaching the hip joint accurately presents a specific anatomical challenge. The femoral head sits deep beneath layers of muscle and soft tissue; without real-time image guidance, placing a scaffold injection precisely at the cartilage defect site is not reliably achievable from the surface.

Ultrasound guidance resolves that problem. During the appointment, the clinician uses live imaging to visualise the joint space, map the location and extent of the chondral defect, and steer the needle to the exact target site — all without a surgical incision or general anaesthetic. The patient is awake and the whole procedure takes place in an outpatient clinic setting.

The single appointment covers every stage of the process: imaging review, defect mapping, the injection itself, and intravenous antibiotic cover as standard. Once placed at the defect site, ChondroFiller gels in position rather than dispersing into the broader joint space — a property that matters in the hip, where the ball-and-socket geometry would otherwise limit how much scaffold remains in contact with the worn surface.

Patients attend, receive the treatment, and go home the same day. There is no theatre admission, no recovery ward, and no wound to manage.

Who is a suitable candidate

Deciding whether ChondroFiller injection is appropriate for a particular hip depends on defect type, severity, and — critically — an accurate diagnosis of where the pain is actually coming from.

The injectable pathway is indicated across a wider range of pathology than the original surgical implant form. Clinically, it targets both focal Grade III or IV chondral lesions and more diffuse Kellgren-Lawrence Grade III or IV osteoarthritis affecting the femoral head or acetabulum. Femoroacetabular impingement (FAI) with associated cartilage wear is a supported indication, reflected in published hip outcomes data covering cam and pincer morphology alongside focal defects.

Patients who are not surgical candidates — whether because of age, comorbidities, or anaesthetic risk — represent a core group for whom this outpatient pathway offers a genuine alternative rather than a stopgap. The same applies to those who wish to avoid or delay hip replacement whilst preserving function and quality of life.

Where night pain has become the dominant symptom, the priority at assessment is confirming it originates from intra-articular cartilage damage rather than from lumbar spine referral, labral pathology, or periarticular soft-tissue sources. Pain that wakes a patient at night does not in itself confirm cartilage wear as the driver; that distinction shapes the entire treatment plan.

Suitability is determined through specialist assessment — imaging, defect mapping, and a review of the joint's overall condition — not assumed from symptoms alone.

What outcomes the evidence supports

The published outcomes for ChondroFiller in the hip centre on the Harris Hip Score (HHS), a 0–100 functional scale where patients with moderate arthritis typically score in the 50–60 range before treatment. Published data report a mean improvement of approximately +33 points — a gain that moves many patients from substantially limited, pain-driven daily function towards near-normal scores on that scale, which clinical benchmarking regards as a large rather than marginal effect.

For structural confirmation, MOCART MRI scores across the multi-joint published case series range from 70 to 87, figures consistent with scaffold integration and improved cartilage tissue signal on imaging. These results span more than 19,000 cases globally. The knee evidence base is the most mature; hip-specific data are positive but represent a smaller published cohort, and patients should expect that distinction to form part of the specialist discussion at assessment.

The adverse-event profile across the literature is a complaint rate of approximately 0.06% — low for any intra-articular device — though individual risk is always confirmed at consultation.

One limitation warrants plain statement: no published standalone randomised controlled trial has measured nocturnal or sleep-disrupting pain as a primary endpoint for ChondroFiller in the hip. The mechanistic rationale — reducing articular friction and cushioning exposed subchondral bone — applies directly to the conditions that sustain pain through the night, but a dedicated sleep-pain trial has not been conducted. The evidence is encouraging and the reasoning is coherent; this specific gap remains open.

Combination approaches, maintenance, and next steps

For patients with more advanced joint changes — Kellgren-Lawrence Grade III or IV disease affecting both the cartilage surfaces and the synovial environment — a dual-injection protocol may be considered within the same clinic visit. In this approach, ChondroFiller (2.3 mL) targets the bone-end cartilage as the regenerative scaffold component; Arthrosamid, a non-regenerative polyacrylamide hydrogel (6 mL), addresses the synovial environment separately. The two act through entirely different mechanisms in different compartments and should not be conflated: ChondroFiller is the scaffold intended to support endogenous cartilage repair; Arthrosamid provides synovial cushioning and remains permanently in the joint. Guide cost for the combined protocol is approximately £6,000.

For patients who respond well, a clinic-specific structured follow-up — annual MRI review and bi-annual top-up injections — offers ongoing cartilage monitoring rather than repeated acute treatment. This is a formalised service pathway rather than an industry-standard protocol; its scope and scheduling are agreed at consultation rather than assumed.

Guide costs at London Cartilage Clinic on Harley Street range from approximately £3,000 to £8,000 depending on defect extent and whether combination therapy is indicated — indicative figures that are confirmed with the treating clinician at assessment. Professor Paul Y. F. Lee, who leads the hip cartilage service, was the first clinician in the UK to deliver ChondroFiller as an injectable.

Patients at the stage where hip pain is disrupting sleep are generally at a point where a specialist cartilage assessment offers the most traction. That assessment maps defect size, depth, and location through dedicated imaging — not just plain X-ray bony grading — and separates intra-articular cartilage wear from other nocturnal pain sources such as labral pathology or lumbar referral. The question of which treatment pathway, if any, is appropriate follows from that diagnostic clarity rather than preceding it.